AMG 162 (Denosumab) Phase 3 Study (DESIRABLE Study) in Participants With Rheumatoid Arthritis on Disease-modifying Antirheumatic Drugs (DMARDs) Treatment (DESIRABLE)
A Confirmatory Study of AMG 162 (Denosumab) in Patients With Rheumatoid Arthritis on DMARDs Treatment (Phase III)
Sponsor: Daiichi Sankyo
A NA clinical study on Rheumatoid Arthritis, this trial is completed. The trial is conducted by Daiichi Sankyo and has accumulated 12 data snapshots since 2013. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
12 versions recorded-
Sep 2024 — Present [monthly]
Completed NA
-
Jul 2024 — Sep 2024 [monthly]
Completed NA
-
Mar 2024 — Jul 2024 [monthly]
Completed NA
-
Jan 2021 — Mar 2024 [monthly]
Completed NA
-
Mar 2020 — Jan 2021 [monthly]
Completed NA
▶ Show 7 earlier versions
-
Jan 2020 — Mar 2020 [monthly]
Completed NA
-
Jun 2018 — Jan 2020 [monthly]
Completed NA
-
Oct 2017 — Jun 2018 [monthly]
Completed NA
Status: Active Not Recruiting → Completed
-
Sep 2017 — Oct 2017 [monthly]
Active Not Recruiting NA
-
Jul 2017 — Sep 2017 [monthly]
Active Not Recruiting NA
Phase: PHASE3 → NA
-
Feb 2017 — Jul 2017 [monthly]
Active Not Recruiting PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE3
First recorded
Oct 2013
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Daiichi Sankyo
For direct contact, visit the study record on ClinicalTrials.gov .